SG10201809428UA - Insulin receptor partial agonists - Google Patents

Insulin receptor partial agonists

Info

Publication number
SG10201809428UA
SG10201809428UA SG10201809428UA SG10201809428UA SG10201809428UA SG 10201809428U A SG10201809428U A SG 10201809428UA SG 10201809428U A SG10201809428U A SG 10201809428UA SG 10201809428U A SG10201809428U A SG 10201809428UA SG 10201809428U A SG10201809428U A SG 10201809428UA
Authority
SG
Singapore
Prior art keywords
partial agonists
insulin receptor
receptor partial
insulin
dimers
Prior art date
Application number
SG10201809428UA
Inventor
Songnian Lin
Lin Yan
Pei Huo
Dmitri Pissarnitski
Danqing Feng
Ravi Nargund
Yuping Zhu
Ahmet Kekec
Christina Madsen-Duggan
Zhi-Cai Shi
Zhicai Wu
Yingjun Mu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG10201809428UA publication Critical patent/SG10201809428UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

INSULIN RECEPTOR PARTIAL AGONISTS OF THE DISCLOSURE Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed. 5 [No Fig Available] 10 [Fig 1]
SG10201809428UA 2014-11-21 2015-11-19 Insulin receptor partial agonists SG10201809428UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
SG10201809428UA true SG10201809428UA (en) 2018-11-29

Family

ID=54838417

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201809428UA SG10201809428UA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809457YA SG10201809457YA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809427SA SG10201809427SA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG11201704064TA SG11201704064TA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG10201809457YA SG10201809457YA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809427SA SG10201809427SA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG11201704064TA SG11201704064TA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Country Status (27)

Country Link
US (4) US20170355743A1 (en)
EP (4) EP3660040A3 (en)
JP (5) JP6484337B2 (en)
KR (2) KR102101136B1 (en)
CN (2) CN112494656B (en)
AR (1) AR102712A1 (en)
AU (3) AU2015349890B2 (en)
BR (3) BR122024000903A2 (en)
CA (2) CA2966765C (en)
CL (3) CL2017001288A1 (en)
CO (1) CO2017004976A2 (en)
CR (1) CR20170208A (en)
DO (1) DOP2017000124A (en)
EA (1) EA036714B1 (en)
ES (1) ES2946247T3 (en)
GT (1) GT201700104A (en)
IL (1) IL252257A0 (en)
MX (3) MX2017006651A (en)
NI (1) NI201700060A (en)
PE (1) PE20170957A1 (en)
PH (1) PH12017500935A1 (en)
SG (4) SG10201809428UA (en)
SV (1) SV2017005445A (en)
TN (1) TN2017000178A1 (en)
TW (1) TW201625673A (en)
WO (1) WO2016081670A2 (en)
ZA (1) ZA201703238B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020295A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
SG10201809428UA (en) 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists
AR105616A1 (en) 2015-05-07 2017-10-25 Lilly Co Eli FUSION PROTEINS
US10953076B2 (en) 2016-05-24 2021-03-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and GLP-1 analogues
WO2017205309A1 (en) * 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
CN109891237B (en) * 2016-10-24 2022-08-23 诺和诺德股份有限公司 Bioassay of insulin preparations
AU2018317810A1 (en) 2017-08-17 2020-03-19 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028864A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN112898172B (en) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 Synthesis method of amphiphilic functional group compound capable of being enzymolyzed by carboxypeptidase
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
KR20230079068A (en) * 2020-09-03 2023-06-05 다인 세라퓨틱스, 인크. Method for preparing protein-oligonucleotide complexes
EP4210729A2 (en) * 2020-09-09 2023-07-19 Merck Sharp & Dohme LLC Insulin receptor partial agonists
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
WO1999064045A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
DE19908041A1 (en) * 1999-02-24 2000-08-31 Hoecker Hartwig Covalently bridged insulin dimers
KR100449454B1 (en) 2000-10-02 2004-09-21 이현철 Vector for Curing Diabetes Mellitus Containing Gene of Single-chain Insulin Analog
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
EP2226316B1 (en) 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
KR100507796B1 (en) 2003-04-03 2005-08-17 한미약품 주식회사 Peg-biologically active polypeptide homodimer conjugate having enhanced half life in blood and process for the preparation thereof
ATE517119T1 (en) 2003-12-03 2011-08-15 Novo Nordisk As SINGLE CHAIN INSULIN
EP1807105A2 (en) 2004-10-27 2007-07-18 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
ES2545533T3 (en) 2004-11-01 2015-09-11 The Regents Of The University Of California Compositions and methods for biomolecule modification
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104737A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2054437A2 (en) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
CN101983066B (en) 2008-01-30 2016-06-29 印第安那大学科技研究公司 Insulin prodrug based on ester
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI394580B (en) * 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
ES2650621T3 (en) * 2008-10-17 2018-01-19 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US8481485B2 (en) 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
CN103068842B (en) * 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 Insulin receptor INSR is had highly active single-chain insulin agonist
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
JP2013540771A (en) * 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス Novel N-terminally modified insulin derivative
AU2012328407A1 (en) * 2011-10-27 2014-05-22 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
JP6387008B2 (en) * 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Insulin analog dimer
JP2016517404A (en) 2013-03-15 2016-06-16 ユニベルシテ ドゥ ジュネーブ Insulin production induction method and use thereof
WO2015051052A2 (en) * 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2015073575A2 (en) * 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
EP3098235A4 (en) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
SG10201809428UA (en) * 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists

Also Published As

Publication number Publication date
DOP2017000124A (en) 2017-08-15
CN108064173A (en) 2018-05-22
SG10201809457YA (en) 2018-11-29
KR102049647B1 (en) 2019-11-29
JP2019014734A (en) 2019-01-31
JP2018501203A (en) 2018-01-18
JP2019011357A (en) 2019-01-24
KR20190069622A (en) 2019-06-19
JP6943825B2 (en) 2021-10-06
CN112494656B (en) 2024-01-30
EP3660041B1 (en) 2023-04-19
AU2018211208B2 (en) 2020-09-10
WO2016081670A3 (en) 2016-08-04
EP3221343A2 (en) 2017-09-27
AU2015349890B2 (en) 2018-08-30
US10017556B2 (en) 2018-07-10
CL2019001144A1 (en) 2019-07-19
PE20170957A1 (en) 2017-07-13
EA036714B1 (en) 2020-12-10
AU2015349890A1 (en) 2017-06-01
CN108064173B (en) 2021-05-18
IL252257A0 (en) 2017-07-31
JP6703068B2 (en) 2020-06-03
CL2019001143A1 (en) 2019-07-19
ES2946247T3 (en) 2023-07-14
EP3666792A2 (en) 2020-06-17
JP2019014735A (en) 2019-01-31
ZA201703238B (en) 2018-05-30
PH12017500935A1 (en) 2017-11-27
BR112017010481A8 (en) 2023-04-11
AU2018211207B2 (en) 2020-04-09
US20180291078A1 (en) 2018-10-11
SV2017005445A (en) 2018-04-04
CR20170208A (en) 2017-07-17
NI201700060A (en) 2017-07-18
EP3660040A2 (en) 2020-06-03
KR102101136B1 (en) 2020-04-14
MX2020014121A (en) 2021-03-25
CA2966765A1 (en) 2016-05-26
SG10201809427SA (en) 2018-11-29
TN2017000178A1 (en) 2018-10-19
MX2017006651A (en) 2017-08-21
CN112494656A (en) 2021-03-16
US10183981B2 (en) 2019-01-22
US10800827B2 (en) 2020-10-13
US20170107268A1 (en) 2017-04-20
EP3660041A1 (en) 2020-06-03
TW201625673A (en) 2016-07-16
CO2017004976A2 (en) 2017-10-10
BR122024000903A2 (en) 2024-02-27
JP6484337B2 (en) 2019-03-13
CA3014641A1 (en) 2016-05-26
US20190092833A1 (en) 2019-03-28
EP3666792A3 (en) 2020-07-29
CA3014641C (en) 2020-08-18
AU2018211208A1 (en) 2018-08-16
EA201791117A1 (en) 2017-11-30
AR102712A1 (en) 2017-03-22
EP3221343B1 (en) 2020-09-16
US20170355743A1 (en) 2017-12-14
CA2966765C (en) 2020-04-14
MX2020014120A (en) 2021-03-25
AU2018211207A1 (en) 2018-08-16
SG11201704064TA (en) 2017-06-29
GT201700104A (en) 2018-11-27
JP6931033B2 (en) 2021-09-01
JP2020097572A (en) 2020-06-25
KR20170084300A (en) 2017-07-19
WO2016081670A2 (en) 2016-05-26
CL2017001288A1 (en) 2017-12-15
EP3660040A3 (en) 2020-07-29
BR122024000898A2 (en) 2024-02-27
BR112017010481A2 (en) 2018-04-03

Similar Documents

Publication Publication Date Title
SG10201809457YA (en) Insulin receptor partial agonists
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2017005920A (en) Anti-tim3 antibodies and methods of use.
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MA40579A (en) Anti-cll-1 antibodies and immunoconjugates
MX2020004073A (en) Seed train processes and uses thereof.
MX2016015162A (en) Anti-gpc3 antibodies and immunoconjugates.
MX2020012893A (en) Protein formulations.
MX2019011297A (en) Insulin analog complex with reduced affinity for insulin receptor and use thereof.
MX2016016233A (en) Anti-lgr5 antibodies and uses thereof.
MX2016015280A (en) Anti-brdu antibodies and methods of use.
NZ719451A (en) Glucagon analog for treatment of severe hypoglycemia
MA40642A (en) Novel peptide derivatives and uses thereof
MY167350A (en) Fat-and-oil composition and chocolate
EA201991576A1 (en) PARTIAL INSULIN RECEPTOR AGONISTS
NZ744340A (en) Anti-jagged1 antibodies and methods of use
UA99992U (en) 2,34-tetrahydropyridin-6-thiolate